2-phenylpyrazolo[4,3-d]pyrimidin-5,7-(4H,6H)-dione | 1190305-82-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-phenylpyrazolo[4,3-d]pyrimidin-5,7-(4H,6H)-dione
• 英文别名: 2-phenyl-4H-pyrazolo[4,3-d]pyrimidine-5,7-dione
• CAS: 1190305-82-8
• 化学式: C₁₁H₈N₄O₂
• 分子量: 228.21
• InChiKey: KFZIPDBORAJIAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-phenylpyrazolo[4,3-d]pyrimidin-5,7-(4H,6H)-dione 在 ammonium hydroxide 、 N,N-二甲基苯胺 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 2.33h， 生成 tert-butyl 4-(7-amino-2-phenyl-2H-pyrazolo[4,3-d]pyrimidin-5-yl)piperazine1-carboxylate
  参考文献：
  名称：

  5-氨基烷基氨基和5-哌嗪基部分在7-氨基吡唑并[4,3-d]嘧啶核上的作用在影响腺苷A1和A2A受体的亲和力和选择性方面。

  摘要：

  合成了新的7-氨基-2-苯基吡唑并[4,3-d]嘧啶衍生物，该衍生物在5-位被芳基（烷基）氨基和4-取代的哌嗪-1-基部分取代，目的是：靶向人（h）腺苷A1和/或A2A受体亚型。总体而言，新的衍生物1-24对脱靶hA2B和hA3 ARs缺乏亲和力或没有亲和力。5-（4-羟基苯乙氨基）-衍生物12对hA2A AR表现出良好的亲和力（Ki = 150 nM）和最佳选择性，而5-苄基氨基取代的5显示出最佳的hA2A（Ki = 123 nM）和A1组合AR亲和力（Ki = 25 nM）。5-苯乙基氨基部分（化合物6）实现了纳摩尔亲和力（Ki = 11 nM）和对hA1 AR的良好选择性。5-（N4-取代的哌嗪-1-基）衍生物15-24以高纳摩尔范围内的亲和力结合hA1 AR亚型。

  DOI：

  10.1080/14756366.2016.1247060
• 作为产物：
  描述：

  三光气 、 4-Amino-1-phenyl-3-pyrazol-carbonsaeureamid 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 8.0h， 以55%的产率得到2-phenylpyrazolo[4,3-d]pyrimidin-5,7-(4H,6H)-dione
  参考文献：
  名称：

  2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a New Scaffold To Obtain Potent and Selective Human A₃ Adenosine Receptor Antagonists: New Insights into the Receptor−Antagonist Recognition

  摘要：

  A molecular simplification approach of previously reported 2-arylpyrazolo[3,4-c]quinolin-4-ones was applied to design 2-arylpyrazolo[4,3-d]pyrimidin-7-one derivatives as new human A(3) adenosine receptor antagonists. Substituents with different lipophilicity and steric hindrance were introduced at the 5-position of the bicyclic Scaffold (R-5 = H, Me, Et, Ph, CH2Ph) and on the 2-phenyl ring (OMe, Me). Most of the synthesized derivatives were highly potent hA(3) adenosine receptor antagonists, the best being the 2-(4-methoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-one (K-i = 1.2 nM). The new compounds were also highly selective, being completely devoid of affinity toward hA(1), hA(2A), and hA(2B) adenosine receptors. On the basis of the recently published human A(2A) receptor crystallographic information, we propose it novel receptor-driven hypothesis to explain both A(3) AR affinity and A(3) versus A(2A) Selectivity profiles of these new antagonists.

  DOI：

  10.1021/jm900718w

文献信息

• P2X3 and/or P2X2/3 compounds and methods
  申请人：Asana BioSciences, LLC

  公开号：US10611768B2

  公开（公告）日：2020-04-07

  The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R7 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient.

  本公开提供了新型化合物以及制备和使用这些化合物的方法。在一个实施方案中，这些化合物具有式（I）的结构，其中 R1-R7 在此定义。在另一个实施方案中，这些化合物可用于调节 P2X3 或 P2X2/3 受体中的一种或两种。在另一个实施方案中，通过给患者施用一种或多种化合物，这些化合物可用于治疗患者的疼痛。在另一个实施方案中，通过向患者施用一种或多种化合物，这些化合物可用于治疗患者的呼吸功能障碍。
• P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS
  申请人：Asana BioSciences, LLC

  公开号：US20180093991A1

  公开（公告）日：2018-04-05

  The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R 1 -R 7 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X 3 or P2X 2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient.